![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1454252
¼¼°èÀÇ ¼Ò¾Æ¿ë °ü·ù ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°Global Pediatric Perfusion Market, By Product Type, By Application, By End User, By Geography |
¼¼°è ¼Ò¾Æ¿ë °ü·ù ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 5¾ï 7,470¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2031³â¿¡ °ÉÃÄ 5.4%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇßÀ¸¸ç, 2031³â¿¡´Â 8¾ï 7,530¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ ¼¼ºÎÁ¤º¸ | ||
---|---|---|---|
±âÁسâ | 2023³â | 2023³â/2024³â ½ÃÀå ±Ô¸ð | 5¾ï 7,470¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2019-2023³â | ¿¹Ãø ±â°£ | 2024-2031³â |
¿¹Ãø±â°£ 2023/2024-2030³â/2031³â CAGR: | 5.40% | 2030³â/2031³â °¡Ä¡ ¿¹Ãø | 8¾ï 7,530¸¸ ´Þ·¯ |
¼Ò¾Æ¿ë °ü·ù´Â °³½É¼ú Áß¿¡ ½ÉÆó ¿ìȸ(CPB)¸¦ ¹Þ´Â ¼Ò¾ÆÀÇ ¼øÈ¯°è¸¦ ÅëÇØ Ç÷¾×À» °ø±ÞÇÏ´Â °ÍÀÔ´Ï´Ù. CPB´Â ¼ö¼úÀÇ Æ¯Á¤ ºÎºÐ¿¡¼ ½ÉÀåÀÌ ¸ØÃß´Â µ¿¾È ¼øÈ¯°ú ÆóÀÇ °¡½º ±³È¯À» À¯ÁöÇϱâ À§ÇØ Àΰø ½ÉÆó ÀåÄ¡¸¦ ÅëÇØ ȯÀÚÀÇ Ç÷¾× ¼øÈ¯À» ¿ìȸÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. ¼Ò¾Æ¿ë °ü·ù¿¡´Â ¼ºÀΠȯÀÚ¿Í ¼Ò¾Æ ȯÀÚÀÇ ÇØºÎÇÐÀû, »ý¸®ÇÐÀû Â÷ÀÌ¿¡ ´ëÀÀÇϱâ À§ÇÑ Æ¯¼ö ÀåÄ¡, ±â¼ú ¹× ±â¼úÀÌ ÇÊ¿äÇÕ´Ï´Ù. Áö³ ¼ö½Ê³âµ¿¾È °ü·ù ±â¼úÀÇ Áøº¸, ȸ·Î ¼³°èÀÇ °³¼±, ¼Ò¾Æ¿¡ ¸ÂÃá ¼ö¼ú ÀýÂ÷ÀÇ Çõ½Å µîÀ¸·Î ¼ö¼úÀÇ ¼º°ø·üÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ±×·¯³ª ¼±Ãµ¼º ½ÉÀå ÁúȯÀº ¿©ÀüÈ÷ ¼¼°è À¯¾Æ »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎ Áß ÇϳªÀÔ´Ï´Ù.
¼¼°èº¸°Ç±â±¸(WHO)ÀÇ Ãß°è¿¡ µû¸£¸é ¼±Ãµ¼º ½ÉÀ庴(CHD)Àº Ãâ»ý¾ÆÀÇ °ÅÀÇ 1%¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁúȯÀÔ´Ï´Ù. Áø´Ü±â¼úÀÇ Çâ»ó¿¡ ÀÇÇØ CHDÀÇ Á¶±â ¹ß°ßÀÌ °¡´ÉÇÏ°Ô µÇ¾î, ¼Ò¾Æ ½ÉÀå¿Ü°ú ¼ö¼úÀÇ Áøº¸¿Í ÇÔ²² »ýÁ¸À²°ú Ä¡·á ¼ºÀûÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ±× °á°ú ¼Ò¾Æ ½ÉÀå ¼ö¼ú, µû¶ó¼ ¼Ò¾Æ¿ë °ü·ù ¼ºñ½ºÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖ´Â ¼Ò¾ÆÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¼Ò¾Æ¿ë °ü·ù´Â Àΰø ½ÉÆó ÀåÄ¡¸¦ »ç¿ëÇÏ¿© ½ÉÀå ¼ö¼ú Áß ¼Ò¾ÆÀÇ ½ÉÆó ±â´ÉÀ» Áö¿øÇÕ´Ï´Ù. ´õ ¸¹Àº ½Å»ý¾Æ¿Í À¯¾Æ°¡ CHD·Î Áø´ÜµÇ¾î ¼öÁ¤ ¼ö¼ú°ú ¿ÏÈ ¼ö¼úÀ» ¹ÞÀ»¼ö·Ï Ư¼ö °ü·ù ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼ö¼úÀÇ Áøº¸´Â º¹ÀâÇÑ ½ÉÀå ¼ö¼úÀÌ ´õ À̸¥ ´Ü°è¿¡¼ ÀÌ·ç¾îÁö°Ô µÇ¾ú°í, ¼Ò¾Æ CHD ȯÀÚÀÇ ¼ö¸í°ú »îÀÇ ÁúÀÌ Áõ°¡Çß½À´Ï´Ù.
±×·¯³ª ¼Ò¾Æ¿ë °ü·ù ½ÃÀåÀº °úÁ¦¿¡µµ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ ½ÉÀå ¼ö¼úÀÇ °í°¡ÀÇ ºñ¿ëÀº ƯÈ÷ Á¾ÇÕÀûÀÎ ÀÇ·á º¸ÇèÀÌ Àû¿ëµÇÁö ¾Ê´Â Áö¿ª¿¡¼´Â °Ç° °ü¸® ½Ã½ºÅÛ°ú °¡Á·¿¡°Ô Å« °æÁ¦Àû ºÎ´ãÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼Ò¾Æ¿ë °ü·ù¿¡´Â Ư¼ö Àü¹® Áö½ÄÀÌ ÇÊ¿äÇϸç ÈÆ·ÃÀ» ¹ÞÀº ¼Ò¾Æ¿ë °ü·ù Àü¹®ÀÇÀÇ ºÎÁ·ÀÌ ÁöÀûµÇ¾ú½À´Ï´Ù. ¶Ç ´Ù¸¥ °úÁ¦´Â °ü·ù ÀåÄ¡ ½ÃÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖ´Â ¿ÀÇÁÆßÇÁ ¼ö¼ú¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¼úÀº ½ÉÀåÀ» ¸ØÃßÁö ¾Ê°í ¼öÇàµÇ±â ¶§¹®¿¡ Àΰø ½ÉÆó ÀåÄ¡°¡ ÇÊ¿ä ¾øÀ¸¸ç °ü·ù ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ÁÙ¾îµé ¼ö ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸ÇÏ°í ¼Ò¾Æ¿ë °ü·ù ½ÃÀå¿¡´Â ƯÈ÷ ¼ÒÇüÈµÈ °ü·ù ÀåÄ¡ÀÇ ±â¼ú Çõ½Å°ú °³Ã´¿¡ Å« ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â ½Å»ý¾Æ¿Í À¯¾ÆÀÇ »ý¸®Àû ¿ä±¸¿¡ ´õ ÀûÇÕÇϸç, º¸´Ù Á¤È®ÇÑ Á¦¾î¿Í ÇÕº´Áõ °¨¼Ò¸¦ Á¦°øÇÕ´Ï´Ù. À̰ÍÀº ¼Ò¾Æ ½ÉÀå ÀÇ·áÀÇ Å« Áøº¸À̸ç,ÀÌ ½ÃÀåÀÇ ±â¾÷¿¡°Ô ¸Å·ÂÀûÀÎ ±âȸ¸¦ Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ °Ç° °ü¸® ÀÎÇÁ¶ó°¡ È®´ëµÇ°í ¼Ò¾Æ ½ÉÀå ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÈ ½ÅÈï ½ÃÀå¿¡µµ ¼ºÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼´Â ÀÇ·á ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ°í ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.
°á·ÐÀûÀ¸·Î, ÀÇ·á Áøº¸°¡ °è¼ÓµÇ´Â µ¿¾È ºñ¿ë, ±³À° ¹× ±â¼ú°ú °ü·ÃµÈ °úÁ¦¿¡ Àü·«ÀûÀ¸·Î ´ëóÇÒ ¼ö ÀÖ´Ù¸é ¼¼°è ¼Ò¾Æ¿ë °ü·ù ½ÃÀåÀº ¼ºÀåÇÒ ¼öÀÖ´Â ÁÁÀº À§Ä¡¿¡ ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü¿Í ÀÇ·á Á¦°ø¾÷ü´Â ¼Ò¾Æ ÀÇ·á¿ëÀ¸·Î ¼³°èµÈ Ư¼öÇÏ°í ºñ¿ë È¿À²ÀûÀÌ¸ç ±â¼úÀûÀ¸·Î ÷´Ü °ü·ù ½Ã½ºÅÛ¿¡ ÅõÀÚÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
The global pediatric perfusion market size was valued at US$ 574.7 Mn in 2023 and is expected to reach US$ 875.3 Mn by 2031 growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2023/2024: | US$ 574.7 Mn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 - 2031 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 5.40% | 2030/2031 Value Projection: | US$ 875.3 Mn |
Pediatric perfusion is the delivery of blood through the circulatory system in children undergoing cardiopulmonary bypass (CPB) during open heart surgery. CPB involves diverting the patient's blood circulation through a heart-lung machine to maintain circulation and lung gas exchange while the heart is stopped during specific parts of the surgical repair. Pediatric perfusion requires specialized equipment, techniques, and skills to handle the anatomical and physiological differences between adult and pediatric patients. Over the past few decades, procedural success rates have significantly improved due to advancements in perfusion technologies, circuit design modifications, and innovations in surgical techniques tailored for children. However, congenital heart defects continue to be one of the major causes of infant mortality worldwide.
The global pediatric perfusion market is experiencing growth primarily due to the increasing incidence of congenital heart diseases (CHD), a condition affecting nearly 1% of live births according to World Helath Organization (WHO) estimates. Improved diagnostic techniques have led to the early identification of CHD, which, coupled with advancements in pediatric cardiac surgical procedures, has improved survival rates and outcomes. Consequently, this has elevated the number of children who can benefit from pediatric cardiac surgeries and, by extension, pediatric perfusion services.
Pediatric perfusion involves the use of a heart-lung machine to support the child's cardiopulmonary functions during cardiac surgery. As more newborns and infants are diagnosed with CHD and undergo corrective or palliative surgeries, the demand for specialized perfusion equipment has grown. The surgical advancements have allowed for complex cardiac interventions to be performed at earlier stages of life, extending the longevity and quality of life of pediatric CHD patients.
However, the pediatric perfusion market does face challenges. The high cost of pediatric cardiac surgeries can be a significant financial burden for healthcare systems and families, particularly in regions without comprehensive health insurance coverage. Moreover, pediatric perfusion requires specific expertise, and there is a recognized gap in the availability of trained pediatric perfusionists. Another challenge is the increasing focus on off-pump surgical procedures, which can limit the market for perfusion equipment. These surgeries, performed without stopping the heart, may not require a heart-lung machine, thereby decreasing the demand for perfusion services.
Despite these challenges, there are substantial opportunities in the pediatric perfusion market, particularly in the innovation and development of miniaturized perfusion equipment. These devices are better suited for the physiological needs of neonates and infants, offering more precise control and reduced complications. This represents a significant advancement in pediatric cardiac care, offering an attractive opportunity for players in the market. There is also potential for growth in emerging markets, where healthcare infrastructure is expanding, and access to pediatric cardiac care is improving. The burgeoning demand for healthcare services in these regions can stimulate market expansion.
In summary, as medical advancements continue, the global pediatric perfusion market is well-positioned for growth, provided that challenges around costs, training, and technology are strategically addressed. Manufacturers and healthcare providers can capitalize on these opportunities by investing in specialized, cost-effective, and technologically advanced perfusion systems designed for pediatric care.